Search Studies

Official Title M16-046: A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects with Moderate to Severe Atopic Dermatitis

Purpose

The purpose of this study is to compare the effectiveness and safety of upadacitinib (ABT-494) versus dupilumab for the treatment of adult subjects (18-75 years of age) with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.

Could this study be right for you?

- Subject must have chronic Atopic Dermatitis (AD) with onset at least 3 years prior to study participation - Subject must have > or = 10% body surface area involvement of atopic dermatitis - Subject must have had inadequate response to topical corticosteroids or topical calcineurin inhibitors within the past 6 months - OR documented systemic treatment for AD within the past 6 months - OR for whom topical treatments are otherwise medically inadvisable - No prior exposure to any JAK inhibitor ( eg. ruxolitinib, tofacitinib, baricitinib, upadacitinib, PF-04965842, and filgotinib) - No prior exposure to dupilumab

Age Range

18 and up

Official Title Aggression and Social-Emotional Information Processing: Neural Correlates During Alcohol Intoxication (Columbus Brain Activity Study or CBA)

Purpose

The purpose of this study is to see how alcohol changes brain activity in different groups of study participants who currently drink at least 10 drinks a week and who have (or do not have) “anger issues”. Brain activity will be measured by Magnetic Resonance Imaging (MRI). Total time you will be in the research study will be for about 4-8 weeks from your initial visit.

Could this study be right for you?

- Healthy men and women 21-55 years of age - Drink on a regular basis (~ 10 alcoholic beverages per week) - With a current history of "anger issues" - Able to complete study sessions during the week

Age Range

21 and up

Official Title Remote assessment of cognition, insulin resistance and omega-3s (RACIR O-3) in breast cancer survivors

Purpose

We are studying the relationships between cognitive function, insulin resistance, and omega-3 fatty acids in the blood and from the diet among breast cancer survivors and women without a history of cancer diagnoses. We hope to learn more about how to potentially protect breast cancer patients from uncomfortable mental changes during and after treatment for breast cancer, such as “chemo brain”.

This is a completely remote study, meaning all study tasks can be completed from the comfort of home. Enrolled participants will complete several online surveys and questionnaires, a Zoom video call for additional assessments, and will be sent materials to complete finger-stick blood sample collections from the comfort of home over a period of 3-4 weeks.

The information we gain from this research study will help us design a future clinical trial to test if dietary interventions can help reduce or prevent cognitive changes like chemo brain in breast cancer patients.

Could this study be right for you?

- Accepts healthy volunteers - YES
- Females
- Age 45-75 years
- Post-menopausal (at least 12 months no menses)
- Stage I-III Breast Cancer diagnosis
- 1-4 years post initial breast cancer diagnosis
- No diagnosis of diabetes
- English speaking

Age Range

45 and up

Official Title Modeling Cognition and Aging

Purpose

The goal of this study is to develop models to better understand decision-making for young adults, older adults, and adults with early Alzheimer’s disease and Mild Cognitive Impairment. This study involves making simple decisions (such as “are there more blue dots or more yellow dots?”) on a computer. Healthy volunteers will also complete basic tasks such as solving puzzles, questionnaires involving numbers, and will be asked to provide basic demographic and health information.

Could this study be right for you?

You may be eligible for this study if: - You are ages 18-25 OR - You are age 60-90 and have NOT been diagnosed with a memory disorder OR - You are age 60-90 and HAVE been diagnosed with either Mild Cognitive Impairment OR mild Alzheimer's disease - You are a native English speaker - You are able to see a computer screen and use hands on keyboard/screen

Age Range

18 and up

Official Title Characterizing Occupational Therapy Intervention for Children with Autism Spectrum Disorders

Purpose

We are actively recruiting typically developing children (ages 6 – 13 years) to participate in a new study looking at attention and sensory processing. In this study, we are investigating what occupational therapy practitioners are doing during therapy for children with autism and to see the effect of occupational therapy on brainwaves and behavior. We will identify differences in brainwaves in children with and without autism. You and your child will be asked to schedule one visit to the EEG lab at Ohio State University. Your visit will last about 2.5 hours and include an hour of EEG testing and one hour of paper-pencil game-like activities measuring attention. We need parent consent, and the parent/guardian will complete assessments about their child as well.

Could this study be right for you?

- Children with no autism or any other medical diagnosis - Your child is between 6 - 13 years of age

Age Range

6 and up

Official Title The Chaperone Study: A multi-center, double-masked, randomized, placebo-controlled, phase III study of the safety and efficacy of atropine 0.1% and 0.01% ophthalmic solutions administered with a microdose dispenser for the reduction of pediatric myopia progression

Purpose

Is your child nearsighted?

Nearsightedness, or myopia, is a condition that results in blurry vision when looking at distant objects.

Myopia happens when the eyeball grows too long or the cornea (the clear front cover of the eye) is too curved.
As a result, light entering the eye is not focused correctly. While glasses and contact lenses can help a person with myopia see clearly, they do not address the underlying stretching of the eye.

Myopia detected in young children tends to increase through the school years . As myopia progresses, it can increase the risk of retinal detachment, cataracts, myopia maculopathy and even blindness. To date, FDA has not approved any drug therapies for reducing myopia progression.

This is why researchers are working to develop new medications and technologies that may help children and teens with this condition. The CHAPERONE Study is a research study testing the safety and effectiveness of microdosed atropine eye solution to see if it slows the progression of myopia in children.

Could this study be right for you?

- Is your child between 3-12 years old?
- Does your child need glasses to see distant objects?
- Is your child able to go to periodic visits at the study clinic to check his/her vision and overall eye health over a 4-year period (11 scheduled visits will be required)?
- Are you available to speak with study staff by phone periodically between your child’s clinic visits to review your child’s experience using study medication?

This study is not for children who have:
- Used atropine or other myopia drug therapies
- Had prior eye surgery
- A systemic disease or condition that can affect their vision

Age Range

3 and up

Official Title Transcranial Direct Current Stimulation Therapy for Sleepiness Related to Shift Work Disorder (tDCS-SWORD)

Purpose

This research study aims to determine the effects of a noninvasive form of brain stimulation on alertness for night shift workers.

Could this study be right for you?

• You are age 18 to 65
• You are currently working the night shift at least 3x/week
• You are suffering from sleepiness at work
• You do not have significant heart and lung problems
• You work within the Columbus, OH area

Age Range

18 and up

Official Title SIJ Stabilization in Long Fusion to the Pelvis: Randomized Controlled Trial

Purpose

To determine whether placement of iFuse-3D across the ssacroiliac joint (SIJ) in the Bedrock configuration provides
clinical and/or radiographic benefits in patients undergoing multilevel spine fusion (MLF) surgery with fixation to the pelvis

Could this study be right for you?

You may be eligible for this study if you are:
1. Age 21-75 at time of screening
2. Scheduled for multilevel (4 or more levels) spinal fusion surgery with planned fixation to the pelvis using S2AI screws
3. Patient has the necessary mental capacity to participate and is physically able to comply with study protocol requirements

Exclusion Criteria
1. The reason for your multilevel spine fusion surgery is any of the following:
a. Congenital neuromuscular disease
b. Prior pelvic fixation (already have S2AI or iliac bolts in place, current surgery indicated to revise this hardware)
c. Grade IV spondylolisthesis
2. Prior sacroiliac joint fusion/fixation on either side
3. Presence of spinal cord stimulator
4. Presence of severe hip pain that could impair functional and quality of life improvement from complex spine surgery
5. Surgeon plans to use iliac screw for pelvic fixation
6. Severe osteoporosis
7. Known allergy to titanium or titanium alloys
8. Current local or systemic infection that raises the risk of surgery
9. Currently receiving or seeking short- or long-term worker's compensation and/or currently involved in injury litigation related to the SIJ or low back pain.
10. Currently pregnant or planning pregnancy in the next 2 years
11. Known or suspected drug or alcohol abuse
12. Fibromyalgia

Age Range

21 and up

Official Title A PHASE 1, SINGLE DOSE PK AND SAFETY STUDY WITH NI-03 FOLLOWED BY A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP DOSE-RANGING STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NI-03 COMPARED TO PLACEBO IN SUBJECTS WITH CHRONIC PANCREATITIS

Purpose

The purpose of this study is to learn if a study drug called NI-03 (also known as Camostat) can help people with chronic pancreatitis. We want to find out what effects, good or bad, the study drug has on the disease. It has been approved in Japan and has been available by prescription for the treatment of the acute pain associated with chronic pancreatitis. The study drug will not be approved for sale in the United States until tests from studies like this one show that it is safe and effective.

Could this study be right for you?

-You are between the ages of 18-80
-You have a diagnosis of chronic pancreatitis
-For males: documented surgical sterilization, sexual abstinence, or agreed upon means of contraception from screening until 28 days after final dose of study medication is required
-For females: documented surgical sterilization, sexual abstinence, postmenopausal status for at least 1 year, or agreed upon means of contraception from screening until 28 days after final dose of study medication is required

Age Range

18 and up

Official Title Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies PROCEED Study)

Purpose

This study is done for researchers to understand pancreatitis and learn how the disease progresses naturally over time.

From the results of this study, researchers hope to develop some lab tests to support early diagnosis of chronic pancreatitis and to also discover any genetic factors that may affect your chances of developing chronic pancreatitis. The results of this study may also provide information that will open opportunities for new drug discovery.

Could this study be right for you?

• You have a history of acute or chronic pancreatitis OR
• You have experienced pain in your abdomen that a doctor has suggested could be due to pancreatitis
• You are between the ages of 18 and 75

Age Range

18 and up

Official Title A Clinical Evaluation of the RheOx Bronchial Rheoplasty System for the Treatment of the Symptoms of Chronic Bronchitis in Adult Patients with COPD

Purpose

RheOx (Gala Therapeutics, Inc.) is an investigational device designed to reduce cough and mucus production through a minimally-invasive procedure. The procedure is performed through a bronchoscope, a thin flexible tube that is inserted through the mouth into the lungs. Once in place, RheOx delivers short bursts of electrical energy to the inner walls of the bronchi, eliminating the mucus-producing cells. Over the next several days, new cells grow and produce less mucus. The right lung is treated first, followed by treatment of the left lung about 1 month later.

RheOx has been studied in three clinical trials and has shown a significant improvement in quality of life and a reduction in cough and mucus at 12 months.

Could this study be right for you?

You may be eligible if:
-You are at least 35 years of age.
-Have chronic bronchitis, defined as productive cough for three months in each of two successive years, whereas other causes of productive cough have been ruled out
-You are receiving guideline directed pharmacotherapy which includes one or more long acting bronchodilator (LAMA, LABA) with or without an inhaled corticosteroid for at least 8 weeks prior to randomization
-You have a cigarette smoking history of at least ten pack years.
-Other criteria that will be reviewed by the study team

You will not be eligible if you have:
- A known unresolved lower respiratory tract infection (e.g., pneumonia, mycobacterium avium-intracellulare infection (MAI), fungus, tuberculosis).
- A steroid-dependent condition requiring more than 10 mg of oral corticosteroid per day.
- Any implantable electronic device (e.g., pacemaker, cardioverter defibrillator, neuro-stimulation devices).
- A history of arrhythmia within past two years which includes tachy-atrial arrhythmias, any ventricular tachy-arrhythmias, or sinus bradycardia with heart rate less than 45 beats per minute.
- Unresolved lung cancer.
- A pulmonary nodule or cavity that in the judgement of the Primary investigator may require intervention during the course of the study.
- Had prior lung surgery, such as lung transplant, LVRS, lobectomy, lung implant/prosthesis, metal airway stent, valves, coils or bullectomy. Prior pneumothorax without lung resection, pleural procedures without surgery, or segmentectomy are acceptable.
- Asthma based on Global Initiative for Asthma (GINA) criteria.
- Smoked (including tobacco, marijuana, e-cigarettes, vaping, etc.) within the last 6 months.
- Unable to walk over 238 feet in 6 minutes.
- Uncontrolled GERD.
- Had prior severe respiratory infection with SARS-CoV-2 (COVID-19) that required ICU support with non-invasive and/or invasive mechanical ventilation.
- A known allergy to nickel.
- Other criteria will be reviewed by the study team

Age Range

35 and up

Official Title A PHASE 3, DOUBLE-MASKED, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT INJECTION IN PATIENTS WITH MODERATELY SEVERE TO SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY

Purpose

The purpose of this 28-week study to investigate the effects and safety of a medication in participants with Center Involving Diabetic Macular Edema (CI-DME). .

Could this study be right for you?

- 18 years and older - Macular edema associated with diabetic retinopathy (DR) - Diagnosis of diabetes mellitus (DM)

Age Range

18 and up